Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% above its 5-year average of -0.01, near the low end of its 5-year range (-2.42–6.55).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
-0.05
DEBT TO EQUITY RATIO AVG 5Y
-0.01
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 607 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Alpha Cognition Inc
Market Cap
$140.02M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
-0.05
5Y Avg
-0.01
Market Cap
$139.73M
Debt to Equity Ratio
0.39
TTM Avg
2.42
3Y Avg
2.91
5Y Avg
2.20
Market Cap
$142.15M
Debt to Equity Ratio
0.67
TTM Avg
1.14
3Y Avg
1.25
5Y Avg
1.10
Market Cap
$136.88M
Debt to Equity Ratio
0.18
TTM Avg
0.22
3Y Avg
0.21
5Y Avg
0.14
Market Cap
$146.12M
Debt to Equity Ratio
0.02
TTM Avg
0.06
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$146.58M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.13
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Cognition Inc (ACOG) | $140.02M | 0.00 | 0.00 | -0.05 | -0.01 |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 0.39 | 2.42 | 2.91 | 2.20 |
| AirSculpt Technologies, Inc. (AIRS)vs › | $142.15M | 0.67 | 1.14 | 1.25 | 1.10 |
| Nyxoah S.A. (NYXH)vs › | $143.60M | 0.63 | 0.53 | 0.32 | 0.25 |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.88M | 0.18 | 0.22 | 0.21 | 0.14 |
| Freenome, Inc. (FRNM)vs › | $135.70M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $135.17M | 0.76 | 0.27 | 2.83 | 1.63 |
| Immuneering Corporation (IMRX)vs › | $146.12M | 0.02 | 0.06 | 0.05 | 0.05 |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.58M | 0.00 | 0.00 | 0.00 | 0.13 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | 0.00 | 0.02 | 0.02 | 0.01 |
Debt/Equity
0.00
Current Ratio
9.03
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.02 |
| 2024-09-30 | -0.76 |
| 2024-06-30 | -0.87 |
| 2024-03-31 | 6.55 |
| 2023-12-31 | -0.26 |
| 2023-09-30 | -0.19 |
| 2023-06-30 | -2.42 |
| 2023-03-31 | 0.89 |
| 2022-12-31 | -0.92 |
| 2022-09-30 | 0.66 |
| 2022-06-30 | 0.27 |
| 2022-03-31 | 0.16 |
| 2021-12-31 | 0.12 |
| 2021-09-30 | 0.73 |
| 2021-06-30 | -0.96 |
| 2021-03-31 | -0.76 |
| 2021-01-31 | 200.84 |
| 2020-01-31 | 0.00 |
| 2019-10-31 | 0.00 |
| 2019-07-31 | 0.00 |
| 2019-04-30 | 0.00 |
| 2019-01-31 | 0.00 |
| 2018-10-31 | 0.00 |
